Company Profile
Tonix Pharmaceuticals Stock Price, News & Analysis
Company overview
Business overview
Tonix Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Tonix Pharmaceuticals is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Tonix Pharmaceuticals follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Tonix Pharmaceuticals sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
TNXP is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Tonix has turned a corner with TONMYA, and that product is now the most important thing in the company. The fibromyalgia approval matters on its own, but the pipeline still gives the story some breadth, especially TNX-4800 in Lyme disease and TNX-1500 in kidney transplant and autoimmune disease.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Source: Tonix Pharmaceuticals
- 02
- 03
Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026
Source: Tonix Pharmaceuticals
- 04
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026
Source: Tonix Pharmaceuticals
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.